

**Clinical trial results:
Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock
(SHOCK) trial****Summary**

| | |
|--------------------------|----------------|
| EudraCT number | 2017-000427-27 |
| Trial protocol | DK |
| Global end of trial date | 17 April 2019 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 09 February 2022 |
| First version publication date | 09 February 2022 |

Trial information**Trial identification**

| | |
|-----------------------|-------------|
| Sponsor protocol code | VIPER-SHOCK |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03092245 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Rigshospitalet, Section for Transfusion Medicine, Capitol Region Blood Bank |
| Sponsor organisation address | Blegdamsvej 9, Copenhagen, Denmark, DK-2100 |
| Public contact | Jakob Stensballe, Section for Transfusion Medicine, Capitol Region Blood Bank, 45 35458587, jakob.stensballe@regionh.dk |
| Scientific contact | Jakob Stensballe, Section for Transfusion Medicine, Capitol Region Blood Bank, +45 35458587, jakob.stensballe@regionh.dk |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 03 November 2019 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 17 April 2019 |
| Global end of trial reached? | Yes |
| Global end of trial date | 17 April 2019 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Efficacy of OctaplasLG® administration as compared to crystalloids (standard of care) in patients with septic shock

Protection of trial subjects:

All patients are admitted to the ICU and therefore in a hospital setting.

Special safety markeres specially related to organfailure are observed during the study such as TACO and TRALI

Background therapy:

All patients receive normal standard of care treatment at the ICU

Evidence for comparator:

Comparator i standard of care

| | |
|---|---------------|
| Actual start date of recruitment | 18 April 2017 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Denmark: 55 |
| Worldwide total number of subjects | 55 |
| EEA total number of subjects | 55 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 16 |
| From 65 to 84 years | 38 |

Subject disposition

Recruitment

Recruitment details:

Patients were screened for inclusion upon admission to the ICU with septic shock

Pre-assignment

Screening details:

Screenings criteria were: 18 years old or above, admitted to the ICU at Bispebjerg Hospital, fulfilling the criteria for septic shock (defined as need for vasopressor and lactate above 2 mmol/l), need for mechanical ventilation, need for naradrenalin at 0,1 mcg/kg/min or above

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Blinding implementation details:

Open label trial

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|------------------|
| Arm title | Intervention arm |
|------------------|------------------|

Arm description: -

| | |
|--|-----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | OctaplasLG |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Dosage according to trial algorithm

| | |
|------------------|------------------|
| Arm title | Standard of care |
|------------------|------------------|

Arm description:

The standard of care group will receive crystalloids as volumen support according to trail algorithm

| | |
|--|-----------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Ringer acetate |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

all types of crystalloids can be used. the most common type i ringer acetate.

| Number of subjects in period 1 | Intervention arm | Standard of care |
|---------------------------------------|------------------|------------------|
| Started | 28 | 27 |
| Completed | 20 | 24 |
| Not completed | 8 | 3 |
| Transferred to other hospital | 1 | - |
| Error in microscan | 1 | 1 |
| Died before 24 hours | - | 2 |
| Died | 3 | - |
| Protocol deviation | 3 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Overall trial |
|-----------------------|---------------|

Reporting group description: -

| Reporting group values | Overall trial | Total | |
|--|---------------|-------|--|
| Number of subjects | 55 | 55 | |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 16 | 16 | |
| From 65-84 years | 38 | 38 | |
| 85 years and over | 1 | 1 | |
| Gender categorical | | | |
| Both male and female patients at 18 years old or above could be included | | | |
| Units: Subjects | | | |
| Female | 25 | 25 | |
| Male | 30 | 30 | |

End points

End points reporting groups

| | |
|--|------------------|
| Reporting group title | Intervention arm |
| Reporting group description: - | |
| Reporting group title | Standard of care |
| Reporting group description: The standard of care group will receive crystalloids as volumen support according to trail algorithm | |

Primary: Change in micorvascular perfusion

| | |
|--|-----------------------------------|
| End point title | Change in micorvascular perfusion |
| End point description: The data describe mean change/diffrence i microvascular perfusion from baseline to 24 hours between the 2 groups | |
| End point type | Primary |
| End point timeframe: From baseline to 24 hours | |

| End point values | Intervention arm | Standard of care | | |
|-----------------------------|-------------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 28 | 27 | | |
| Units: mm/mm2 | | | | |
| log mean (standard error) | | | | |
| PPV | -1.528 (\pm 1.101) | 0 (\pm 0) | | |
| PVD | -2.2931 (\pm 0.2479) | 0 (\pm 0) | | |

Statistical analyses

| | |
|---|-------------------------------------|
| Statistical analysis title | Primary endpoint |
| Comparison groups | Intervention arm v Standard of care |
| Number of subjects included in analysis | 55 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.05 |
| Method | ANCOVA |

Secondary: Mortality at 24h

| | |
|-----------------|------------------|
| End point title | Mortality at 24h |
|-----------------|------------------|

| | |
|---|-----------|
| End point description: Number of death at 24 hours | |
| End point type | Secondary |
| End point timeframe: mortality at 24 hours | |

| End point values | Intervention arm | Standard of care | | |
|-----------------------------|-------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 28 ^[1] | 27 ^[2] | | |
| Units: number | | | | |
| Death | 3 | 2 | | |

Notes:

[1] - ITT analysis

[2] - ITT analysis

Statistical analyses

| | |
|---|-------------------------------------|
| Statistical analysis title | ITT mortality at 24h |
| Comparison groups | Intervention arm v Standard of care |
| Number of subjects included in analysis | 55 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.747 |
| Method | Fisher exact |

Secondary: Mortality at day 30

| | |
|--|---------------------|
| End point title | Mortality at day 30 |
| End point description: number of deaths at day 30 | |
| End point type | Secondary |
| End point timeframe: Mortality at day 30 | |

| End point values | Intervention arm | Standard of care | | |
|-----------------------------|-------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 28 ^[3] | 27 ^[4] | | |
| Units: number | | | | |
| Death | 12 | 7 | | |

Notes:

[3] - ITT analysis

[4] - ITT analysis

Statistical analyses

| | |
|---|-------------------------------------|
| Statistical analysis title | ITT mortality at dag 30 |
| Comparison groups | Intervention arm v Standard of care |
| Number of subjects included in analysis | 55 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.25 |
| Method | Fisher exact |

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

Until day 30

Adverse event reporting additional description:

Only SAR and some SAE of special interests will be recorded at these patients are admitted to an ICU and therefore critical ill and will experience AE all the time without any benefit for safety issues. SAE/SAR are recorded based on the patients medical record.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|------|
| Dictionary name | none |
|-----------------|------|

| | |
|--------------------|---|
| Dictionary version | 0 |
|--------------------|---|

Frequency threshold for reporting non-serious adverse events: 1 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Only SAR and some SAE are recorded for these patients as these are admitted to the ICU. NO SAE or SAR are observed

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported